NDAORALTABLETPriority Review
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JASCAYD (nerandomilast) is a newly approved oral small-molecule tablet from Boehringer Ingelheim launched in October 2025. The mechanism of action and specific therapeutic indication are not yet disclosed in available data. This represents a novel molecular entity entering the market with a 12+ year patent runway.
Growth12.1 years to LOE
As a newly launched product with zero competitive pressure, JASCAYD represents a high-potential growth opportunity with early-stage team expansion and significant commercial runway ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Started Nov 2026
270 enrolled
Idiopathic Inflammatory Myopathies
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Started Sep 2026
466 enrolled
Interstitial Lung Diseases
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Started Jul 2026
448 enrolled
Systemic Sclerosis
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
Started Jul 2026
35 enrolled
Fibrosing Interstitial Lung Disease
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.
Started Jun 2026
120 enrolled
Pulmonary FibrosisInterstitial Lung Disease (ILD)
Worked on JASCAYD at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.